Showing 2291-2300 of 5771 results for "".
- Bausch + Lomb Announces US Launch Of Ocuvite Eye Performance Vitaminshttps://modernod.com/news/bausch-lomb-announces-us-launch-of-ocuvite-eye-performance-vitamins/2476714/Bausch + Lomb announced the US launch of Ocuvite Eye Performance vitamins, which were formulated with seven nutrients that help strengthen the macula. The nutrients protect the eye from stressors such as sun light and blue light emitted from digital devices. These nutrients include lutein
- Clearside Biomedical Announces License Agreement with Aura Biosciences for Suprachoroidal Space Microinjectorhttps://modernod.com/news/clearside-biomedical-announces-license-agreement-with-aura-biosciences-for-suprachoroidal-space-microinjector/2479566/Clearside Biomedical announced its entry into a worldwide licensing agreement with Aura Biosciences for the use of Clearside’s Suprachoroidal Space (SCS) Microinjector to deliver Aura’s proprietary drug candidates into the SCS for the potential treatment of certain ocular cancers, including choro
- EyePoint Pharmaceuticals Announces US Commercialization of Dexycuhttps://modernod.com/news/eyepoint-pharmaceuticals-announces-us-commercialization-of-dexycu/2479573/EyePoint Pharmaceuticals announced the commercial launch of Dexycu (dexamethasone intraocular suspension) 9% in the United States. Dexycu is the first and only FDA approved intraocular steroid for the treatment of postoperative inflammation and is administered as
- SIFI Announces Expansion in the French Market With Acquisition of Dacudoses and Novoptinehttps://modernod.com/news/sifi-announces-expansion-in-the-french-market-with-acquisition-of-dacudoses-and-novoptine/2479574/Italian ophthalmic company SIFI has announced the acquisition of Dacudoses and Novoptine antiseptic brands in France from Laboratoire Gifrer Barbezat. Terms of the deal were not disclosed. Dacudoses is the leading reimbursed RX brand of the French ophthalmic antiseptic segment, pres
- Ocular Therapeutix Announces Commercial Launch of Dextenzahttps://modernod.com/news/ocular-therapeutix-announces-commercial-launch-of-dextenza/2476704/Ocular Therapeutix announced the commercial launch in the United States of Dextenza (dexamethasone ophthalmic insert) 0.4 mg for the treatment of ocular inflammation and pain following ophthalmic surgery. Dextenza is the first FDA-approved intracanalicular insert that enables the delivery of drug
- DORC Announces FDA Acceptance of Orphan NDA for Brilliant Blue G Ophthalmic Solutionhttps://modernod.com/news/dorc-announces-fda-acceptance-of-orphan-nda-for-brilliant-blue-g-ophthalmic-solution/2476701/DORC has announced that it has received notification from the FDA that their new drug application (NDA) for Brilliant Blue G ophthalmic solution has been accepted for review. The proposed indication for Brillia
- NuSight Medical Announces Issuance of U.S. Patent Covering the NuLids System for Treating Dry Eye Diseasehttps://modernod.com/news/nusight-medical-announces-issuance-of-u-s-patent-covering-the-nulids-system-for-treating-dry-eye-disease/2476697/NuSight Medical, a medical device company focused on the doctor directed, at-home treatment of dry eye disease, announced that the U.S. Patent Office has issued Patent No. 10,314,763, which is directed to methods related to the treatment of dry eye disease. U.S. Patent No. 10,314,763 cover
- Dompé Announces First Patient Enrolled in Phase 2b Clinical Trial Investigating Dry Eye Disease Drug Candidatehttps://modernod.com/news/dompe-announces-first-patient-enrolled-in-phase-2b-clinical-trial-investigating-dry-eye-disease-drug-candidate/2476687/Dompé Farmaceutici S.p.A and Dompé U.S. announced that the first patient has been enrolled in NGF0118, a multicenter, randomized, double-masked, vehicle-controlled, parallel group study to evaluate the safety and efficacy of rhNGF eye solution vs. vehicle in patients with moderate to severe dry e
- Alnylam Announces Progress with RNAi Therapeutics Platform, Including Oral Route of Administration and CNS and Ocular Deliveryhttps://modernod.com/news/alnylam-announces-progress-with-rnai-therapeutics-platform-including-oral-route-of-administration-and-cns-and-ocular-delivery/2476682/Alnylam Pharmaceuticals announced new advances in its RNAi therapeutics platform, including preclinical results demonstrating oral delivery of GalNAc-conjugated small interfering RNAs (siRNAs) – the molecules that mediate RNAi – directed to a liver target. Oral delivery could broaden the clinical
- Carl Zeiss Meditec Announces Investment in Early Stage MIGS Device Maker MicroOptxhttps://modernod.com/news/carl-zeiss-meditec-announces-investment-in-clinical-stage-migs-device-maker-microoptx/2476679/Carl Zeiss Meditec announced that it has become a shareholder of MicroOptx, a privately held company focused on minimally invasive glaucoma surgery (MIGS) devices for surgical treatment of glaucoma. Their surgical tec